ES2176236T3 - Derivado de indolin-2-ona. - Google Patents

Derivado de indolin-2-ona.

Info

Publication number
ES2176236T3
ES2176236T3 ES94907058T ES94907058T ES2176236T3 ES 2176236 T3 ES2176236 T3 ES 2176236T3 ES 94907058 T ES94907058 T ES 94907058T ES 94907058 T ES94907058 T ES 94907058T ES 2176236 T3 ES2176236 T3 ES 2176236T3
Authority
ES
Spain
Prior art keywords
sub
rent
lower rent
representative
arilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907058T
Other languages
English (en)
Inventor
Toru Chugai Esaki
Takashi Emura
Eiichi Hoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2176236T3 publication Critical patent/ES2176236T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

UN COMPUESTO REPRESENTADO POR LA FORMULA GENERAL (I) Y UN INTERMEDIO PARA LA SINTESIS DEL MISMO (EN LA QUE R{SUB,1} REPRESENTA HALOGENO, ALQUILO INFERIOR, ALCOXI INFERIOR, HIDROXI, NITRO, TRIFLUOMETILO, ALQUILTIO INFERIOR, ACILO, CARBOXI, MERCAPTO O AMINO; R{SUB,2} REPRESENTA HIDROGENO, ALQUILO INFERIOR, ALQUENILO INFERIOR, ALQUINILO INFERIOR, ALCOXI, ACILO, ARILO O HETEROCICLO; R{SUB,3} REPRESENTA ALQUILO INFERIOR, CICLOALQUILO, ARILO O HETEROCICLO; R{SUB,4} REPRESENTA HIDROGENO, ALQUILO INFERIOR, ARILO, HETEROCICLO, -OR{SUB,5}, -SR{SUB,5} O NR{SUB,6}R{SUB,7} (DE R{SUB,5} A R{SUB,7} REPRESENTAN CADA UNO ALQUILO INFERIOR, ETC.); X E Y REPRESENTAN CADA UNO -CH{SUB,2}-, -NHU -O-; Y N REPRESENTA DE 0 A 4). ESTE COMPUESTO PRESENTA UN ANTAGONISMO SELECTIVO CONTRA LOS RECEPTORES DE GASTRINA SIN PRESENTAR LOS EFECTOS SECUNDARIOS PROVOCADOS POR EL ANTAGONISMO CONTRA EL RECEPTOR DE CCK-A Y POR TANTO ES EFICAZ PARA EL TRATAMIENTO Y PREVENCION DE ULCERAS PEPTICAS, LA GASTRITIS, LA ESOFAGUITIS POR REFLUJO Y EL SINDROME DE ZOLLINGER-ELLISON Y PARA EL TRATAMIENTO DE LOS NEOPLASMAS QUE APARECEN EN EL SISTEMA GASTROINTESTINAL.
ES94907058T 1993-02-17 1994-02-17 Derivado de indolin-2-ona. Expired - Lifetime ES2176236T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6729793 1993-02-17
JP16726293 1993-05-31

Publications (1)

Publication Number Publication Date
ES2176236T3 true ES2176236T3 (es) 2002-12-01

Family

ID=26408486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907058T Expired - Lifetime ES2176236T3 (es) 1993-02-17 1994-02-17 Derivado de indolin-2-ona.

Country Status (19)

Country Link
US (5) US5952511A (es)
EP (1) EP0685463B1 (es)
JP (1) JP3419539B2 (es)
KR (1) KR100226310B1 (es)
CN (1) CN1046268C (es)
AT (1) ATE217864T1 (es)
AU (1) AU6044894A (es)
CA (1) CA2156287C (es)
CZ (1) CZ290504B6 (es)
DE (1) DE69430664T2 (es)
ES (1) ES2176236T3 (es)
FI (1) FI112652B (es)
HU (1) HUT74105A (es)
MY (1) MY128102A (es)
NO (1) NO305201B1 (es)
PL (1) PL176710B1 (es)
RU (1) RU2128170C1 (es)
TW (1) TW281669B (es)
WO (1) WO1994019322A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
ES2173163T3 (es) * 1993-11-26 2002-10-16 Tanabe Seiyaku Co Derivados de 2-oxoindolina como antagonistas del receptor de colecistoquinina.
DE69512220T2 (de) * 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. Sulfonamidderivate als aspartylprotease-inhibitoren
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
WO1997033867A1 (en) * 1996-03-11 1997-09-18 Ube Industries, Ltd. Process for the preparation of optically active indole compounds
AU3459497A (en) * 1996-07-12 1998-02-09 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
UA54403C2 (uk) * 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU767728B2 (en) 1998-06-19 2003-11-20 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
DE69922997T2 (de) * 1998-12-04 2005-12-15 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
ATE425142T1 (de) * 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
EP1233958B1 (en) 1999-11-23 2011-06-29 MethylGene Inc. Inhibitors of histone deacetylase
WO2001066142A1 (en) * 2000-03-10 2001-09-13 Chugai Seiyaku Kabushiki Kaisha Preparations for chondrogenesis
US7612065B2 (en) 2000-04-21 2009-11-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-JUN N-terminal kinases (JNK)
EP1363881A2 (en) * 2000-06-21 2003-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1296949A2 (en) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
CA2508290C (en) 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
CN1251698C (zh) * 2003-01-30 2006-04-19 普文英 一种治疗内毒素血症的板蓝根提取物和用途
MX2007005126A (es) * 2004-10-27 2007-07-04 Kissei Pharmaceutical Compuesto de indolina y proceso para producir el mismo.
US20080030974A1 (en) * 2006-08-02 2008-02-07 Abu-Ageel Nayef M LED-Based Illumination System
US20090050905A1 (en) * 2007-08-20 2009-02-26 Abu-Ageel Nayef M Highly Efficient Light-Emitting Diode
WO2010090862A2 (en) * 2009-01-21 2010-08-12 Abu-Ageel Nayef M Illumination system utilizing wavelength conversion materials and light recycling
EP2493297B1 (en) * 2009-10-30 2016-08-17 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
CN102516153B (zh) * 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
KR102254957B1 (ko) 2013-11-22 2021-05-25 씨엘 바이오사이언시즈 엘엘씨 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드)
KR102161674B1 (ko) * 2014-02-18 2020-10-05 주식회사 대웅제약 이사틴 유도체 및 이의 제조방법
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用
CN117777002A (zh) * 2023-12-04 2024-03-29 华南理工大学 一种3,3-二取代氧化吲哚衍生物的不对称合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
JPS62228072A (ja) 1985-12-20 1987-10-06 Kissei Pharmaceut Co Ltd ３−アミノインドリン−２−オン誘導体
JPS62234080A (ja) 1985-12-20 1987-10-14 Kissei Pharmaceut Co Ltd インドリン−２−オン誘導体
US4760083A (en) 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
JPS62270576A (ja) 1986-05-19 1987-11-24 Kissei Pharmaceut Co Ltd イサチン誘導体
JPS62156771A (ja) * 1986-12-19 1987-07-11 Tokyo Shokai:Kk 処方箋処理装置
JPS63156771A (ja) 1986-12-19 1988-06-29 Kissei Pharmaceut Co Ltd ３−アミノインドリン−２−オン誘導体
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
JP3356431B2 (ja) * 1990-08-31 2002-12-16 ワーナー―ランバート・コンパニー Ｃｃｋアンタゴニストに対するプロ―ドラッグ
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
CA2055094A1 (en) * 1990-11-13 1992-05-14 Mark G. Bock Cholecystokinin antagonist
JPH05104510A (ja) * 1991-10-18 1993-04-27 Inax Corp 基板へのモルタル塗布方法

Also Published As

Publication number Publication date
FI112652B (fi) 2003-12-31
KR100226310B1 (ko) 1999-10-15
CZ290504B6 (cs) 2002-08-14
US6207836B1 (en) 2001-03-27
CA2156287C (en) 2005-12-27
CN1046268C (zh) 1999-11-10
PL176710B1 (pl) 1999-07-30
EP0685463A4 (es) 1996-01-03
JPH0748349A (ja) 1995-02-21
CA2156287A1 (en) 1994-09-01
HUT74105A (en) 1996-11-28
TW281669B (es) 1996-07-21
US6031111A (en) 2000-02-29
EP0685463B1 (en) 2002-05-22
MY128102A (en) 2007-01-31
US6127544A (en) 2000-10-03
CN1117727A (zh) 1996-02-28
US6114536A (en) 2000-09-05
NO953235L (no) 1995-10-09
WO1994019322A1 (en) 1994-09-01
FI953866A7 (fi) 1995-08-16
NO953235D0 (no) 1995-08-17
PL310168A1 (en) 1995-11-27
US5952511A (en) 1999-09-14
AU6044894A (en) 1994-09-14
FI953866A0 (fi) 1995-08-16
JP3419539B2 (ja) 2003-06-23
EP0685463A1 (en) 1995-12-06
HU9502415D0 (en) 1996-05-28
KR960701011A (ko) 1996-02-24
DE69430664D1 (de) 2002-06-27
NO305201B1 (no) 1999-04-19
ATE217864T1 (de) 2002-06-15
RU2128170C1 (ru) 1999-03-27
DE69430664T2 (de) 2003-01-30
CZ209695A3 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
ES2176236T3 (es) Derivado de indolin-2-ona.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2079520T3 (es) Nuevos antiepilepticos.
ES2106855T3 (es) Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.
NO996233L (no) Vannrensing ved hjelp av gasshydrat
AU9057191A (en) N-substituted lactams useful as cholecystokinin antagonists
ES2084801T3 (es) Acil compuestos.
MY145670A (en) Heterocyclic compound
TR199801641T2 (xx) Tropan t�revleri bunlar�n haz�rlanmas� ve kullan�m�
ES2164745T3 (es) Procedimiento para purificar y aislar 2'-desoxi-2',2'-difluoronucleosidos.
ES2160237T3 (es) O-carbamoil-fenilalaninol que tiene sustituyente en anillo de benceno, sus sales farmaceuticamente utiles, y metodo para la preparacion de los mismos.
DK0691967T3 (da) Nitrogenholdige kondenserede heterocykliske forbindelser
AR246951A1 (es) Un metodo de tratamiento de residuos de destilacion de diisocianato de tolueno y productos formados por dicho tratamiento.
CO5011105A1 (es) Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
NO943133D0 (no) Benzodiazepinderivater egnet til bruk som CCK-reseptorantagonister
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
NO970356L (no) PTH eller PTHrP antagonister
MX9305510A (es) Compuestos para el tratamiento o profilaxis de desordenes gastrointestinales, cardiovasculares y del sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2181697T3 (es) 4-cianofeniliminoheterociclos.
EA200870346A1 (ru) Удлинители цепи
GT199900113A (es) Inhibidores de las fkbp.
DE59706174D1 (de) Melamin-polycarbonsäureamide und ihre Verwendung als Korrosionsschutzmittel
BRPI0412512A (pt) método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina
PA8473501A1 (es) 2- aminopiridinas que contienen sustituyentes de anillos condensados
ES2079465T3 (es) Iminosilanos.